Amphastar pharmaceuticals reports financial results for the three months ended september 30, 2023

Reports net revenues of $180.6 million for the three months ended september 30, 2023 rancho cucamonga, ca / accesswire / november 8, 2023 / amphastar pharmaceuticals, inc. (nasdaq:amph) ("amphastar" or the "company") today reported results for the three months ended september 30, 2023. third quarter highlights net revenues of $180.6 million for the third quarter gaap net income of $49.2 million, or $0.91 per share, for the third quarter adjusted non-gaap net income of $61.9 million, or $1.15 per share, for the third quarter dr. jack zhang, amphastar's president and chief executive officer, commented: "we are pleased to announce strong results driven by the success of our diabetes portfolio, particularly following the strategic acquisition of baqsimi® and the continued strength of our generic glucagon product.
AMPH Ratings Summary
AMPH Quant Ranking